TG Therapeutics Inc
TGTX
15.72USD-0.31Â (-1.93%)Market ClosedWatchlist
Market Summary
USD15.72-0.31
Market Closed-1.93%
TGTX Alerts
TGTX Stock Price
View Fullscreen
TGTX RSI Chart
TGTX Alerts
TGTX Valuation
TGTX Price/Sales (Trailing)
TGTX Profitability
TGTX Fundamentals
TGTX Revenue
TGTX Earnings
Price Action
Last 7 days
25.1%
Last 30 days
48.0%
Last 90 days
54.3%
Trailing 12 Months
92.9%
How does TGTX drawdown profile look like?
TGTX Financial Health
TGTX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 8.6M | 24.1M | 189.8M | 0 |
| 2022 | 7.9M | 7.0M | 5.0M | 2.8M |
| 2021 | 907.0K | 2.4M | 4.4M | 6.7M |
| 2020 | 152.0K | 152.0K | 152.0K | 152.0K |
| 2019 | 337.0K | 152.0K | 152.0K | 152.0K |
| 2018 | 224.8K | 297.5K | 370.3K | 443.0K |
| 2017 | 283.1K | 240.5K | 231.5K | 152.0K |
| 2016 | 229.4K | 290.5K | 322.5K | 323.0K |
| 2015 | 86.9K | 118.8K | 150.7K | 182.6K |
| 2014 | 36.9K | 42.9K | 49.0K | 55.0K |
| 2013 | 53.5K | 87.5K | 120.6K | 30.8K |
| 2012 | 0 | 0 | 0 | 19.0K |
| 2011 | 0 | 0 | 0 | 0 |
| 2010 | 0 | 0 | 0 | 0 |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TGTX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 28, 2023 | hoberman kenneth | acquired | - | - | 20,000 | - |
| Sep 28, 2023 | echelard yann | acquired | - | - | 20,000 | - |
| Sep 28, 2023 | lonial sagar | sold | - | - | -20,000 | - |
| Sep 28, 2023 | hume daniel | acquired | - | - | 20,000 | - |
| Sep 28, 2023 | charney laurence n | acquired | - | - | 20,000 | - |
| Aug 11, 2023 | weiss michael s | bought | 1,013,000 | 10.13 | 100,000 | ceo and president |
| Jun 23, 2023 | lonial sagar | sold | -814,538 | 23.37 | -34,854 | - |
| Jun 02, 2023 | power sean a | sold | -1,966,370 | 26.7 | -73,647 | chief financial officer |
| Mar 12, 2023 | power sean a | acquired | - | - | 85,000 | chief financial officer |
| Mar 12, 2023 | weiss michael s | acquired | - | - | 985,000 | ceo and president |
Which funds bought or sold TGTX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | Raleigh Capital Management Inc. | added | 5.41 | -18,673 | 10,266 | -% |
| Dec 06, 2023 | CITIGROUP INC | added | 117 | -1,337,530 | 3,622,700 | -% |
| Nov 30, 2023 | Neo Ivy Capital Management | sold off | -100 | -375,000 | - | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -2.51 | -1,601,380 | 781,969 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 159,383 | 159,383 | -% |
| Nov 21, 2023 | Walleye Capital LLC | new | - | 745,486 | 745,486 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 3,904 | 3,904 | -% |
| Nov 21, 2023 | Walleye Trading LLC | added | 309 | 21,861 | 79,713 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 56.04 | -3,066,220 | 3,390,970 | 0.02% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | reduced | -88.00 | -127 | 25.00 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of TG Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Apr 03, 2023 | darwin global management, ltd. | 7.1% | 10,451,241 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 10.67% | 15,502,764 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 03, 2023 | state street corp | 7.17% | 10,415,161 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.3% | 9,132,890 | SC 13G/A | |
| Jul 11, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 6.2% | 8,902,165 | SC 13G/A | |
| Feb 16, 2021 | great point partners llc | 0.0% | 0 | SC 13G/A | |
| Feb 10, 2021 | ra capital management, l.p. | 6.4% | 8,685,471 | SC 13G/A |
Recent SEC filings of TG Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 06, 2023 | 10-Q | Quarterly Report | |
| Nov 01, 2023 | 8-K | Current Report | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading |
Peers (Alternatives to TG Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 30.9B | - | 5.25% | 401813.88% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.5B | 10.7B | 8.54% | -55.34% | -8.79 | 2.86 | -53.67% | -129.46% |
ALNY | 22.2B | 1.7B | 4.15% | -23.37% | -43.62 | 12.9 | 79.37% | 56.87% |
BMRN | 17.9B | 2.3B | 11.05% | -8.44% | 121.62 | 7.74 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 0.84% | -34.33% | 29.1 | 3.43 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.6B | 272.9M | 35.37% | 34.74% | -12.51 | 27.78 | 141.38% | 4.43% |
BBIO | 5.9B | - | 14.36% | 263.35% | -10.02 | 48.33 | 54.84% | -12.96% |
ACAD | 3.6B | 631.9M | -7.32% | 48.57% | -24.01 | 5.65 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.28% | -10.13% | -16.47 | 14.87 | - | -26.24% |
ARWR | 2.6B | 240.7M | -10.83% | -25.35% | -12.82 | 10.93 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 11.36% | -14.92% | 24.59 | 4.38 | 81.69% | -7.29% |
NVAX | 656.6M | 1.0B | -22.00% | -67.89% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.23% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 39.5M | - | 376.67% | 112.17% | -0.61 | - | - | -29.23% |
CRBP | 23.3M | - | 25.24% | 3980.68% | -0.49 | - | - | -13.74% |
TG Therapeutics Inc News
Latest updates
Financials for TG Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 931.6% | 165,815,000 | 16,074,000 | 7,803,000 | 80,000 | 95,000 | 594,000 | 2,016,000 | 2,321,000 | 2,030,000 | 1,545,000 | 793,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 | 38,000 |
| Operating Expenses | -100.0% | - | 60,748,000 | 44,795,000 | 52,143,000 | 35,057,000 | 39,535,000 | 68,888,000 | 95,269,000 | 87,158,000 | 79,036,000 | 89,995,000 | 86,820,000 | 85,760,000 | 50,883,000 | 50,283,000 | 37,998,000 | 60,899,000 | 35,582,000 | 34,727,000 | 54,188,000 | 34,366,000 |
| S&GA Expenses | 6.7% | 32,769,000 | 30,715,000 | 28,068,000 | 22,505,000 | 14,254,000 | 12,638,000 | 20,609,000 | 32,412,000 | 34,899,000 | 34,017,000 | 26,762,000 | 43,859,000 | 35,296,000 | 14,434,000 | 14,261,000 | 7,055,500 | 2,914,000 | 2,716,000 | 2,342,000 | 1,912,500 | 968,000 |
| R&D Expenses | -47.5% | 14,753,000 | 28,122,000 | 15,870,000 | 29,635,000 | 20,801,000 | 26,874,000 | 48,042,000 | 62,646,500 | 51,967,000 | 44,871,000 | 63,094,000 | 42,961,000 | 50,464,000 | 36,449,000 | 36,022,000 | 30,943,500 | 57,985,000 | 32,866,000 | 32,385,000 | 52,275,500 | 33,398,000 |
| EBITDA Margin | - | - | - | - | - | - | -48.84 | -43.15 | -51.16 | - | - | -300 | -1,796 | -1,091 | -1,092 | -1,099 | -1,102 | 22.60 | 13.94 | 4.77 | - | - |
| Interest Expenses | 2.4% | 3,713,000 | 3,627,000 | 2,844,000 | 2,862,000 | 1,648,000 | 3,017,000 | 2,664,000 | 1,079,000 | 1,038,000 | 1,623,000 | 1,898,000 | 1,290,500 | 1,610,000 | 2,228,000 | 1,201,000 | 1,899,000 | 1,537,000 | 1,077,000 | 774,000 | 220,000 | 221,000 |
| EBT Margin | - | - | - | - | - | - | -50.01 | -44.00 | -52.04 | - | - | -308 | -1,838 | -1,137 | -1,137 | -1,137 | -1,137 | -1.14 | -1.14 | -0.57 | - | - |
| Net Income | 100.0% | - | -47,610,000 | -39,232,000 | -52,994,000 | -35,818,000 | -40,510,000 | -69,013,000 | -93,338,500 | -85,637,000 | -78,497,000 | -90,628,000 | -88,218,000 | -87,163,000 | -52,884,000 | -51,116,000 | -39,572,500 | -61,930,000 | -36,212,000 | -35,156,000 | -53,860,000 | -33,951,000 |
| Net Income Margin | - | - | - | -60.52 | -71.22 | -48.98 | -41.44 | -41.26 | -52.04 | -77.84 | -142 | -351 | -1,838 | -1,517 | -1,351 | -1,242 | -1,137 | - | - | - | - | - |
| Free Cashflow | - | - | - | -59,905,000 | -23,873,000 | -34,499,000 | -49,116,000 | -68,696,000 | -86,989,000 | -67,280,000 | -60,344,000 | -81,422,000 | -52,181,000 | -56,621,000 | -43,879,000 | -62,183,000 | -30,427,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | 49.9% | 331 | 221 | 197 | 194 | 218 | 252 | 303 | 380 | 410 | 481 | 549 | 626 | 274 | 295 | 102 | 163 | 93.00 | 107 | 118 | 84.00 | 114 |
| Current Assets | 53.0% | 319 | 209 | 185 | 168 | 183 | 203 | 242 | 331 | 372 | 455 | 535 | 612 | 260 | 281 | 88.00 | 149 | 80.00 | 94.00 | 105 | 79.00 | 110 |
| Cash Equivalents | 56.9% | 152 | 97.00 | 61.00 | 102 | 110 | 147 | 186 | 300 | 327 | 402 | 472 | 553 | 254 | 261 | 52.00 | 114 | 45.00 | 57.00 | 64.00 | 43.00 | 71.00 |
| Inventory | 11.0% | 34.00 | 30.00 | 27.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | -35.4% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | -7.8% | 166 | 180 | 170 | 135 | 117 | 123 | 133 | 142 | 98.00 | 98.00 | 103 | 106 | 103 | 100 | 103 | 124 | 119 | 93.00 | 98.00 | 60.00 | 43.00 |
| Current Liabilities | -20.6% | 58.00 | 73.00 | 63.00 | 53.00 | 36.00 | 43.00 | 55.00 | 65.00 | 88.00 | 88.00 | 92.00 | 88.00 | 78.00 | 68.00 | 63.00 | 84.00 | 80.00 | 56.00 | 61.00 | 39.00 | 40.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | 1.00 | 16.00 | 23.00 | 30.00 | 22.00 | 15.00 | 7.00 | - | - | - | - | - | - | - |
| LT Debt, Non Current | 1.2% | 99.00 | 98.00 | 97.00 | 71.00 | 70.00 | 69.00 | 67.00 | 67.00 | - | - | - | 8.00 | 15.00 | 22.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | - | - |
| Shareholder's Equity | -100.0% | - | 40.00 | 27.00 | 59.00 | 100 | 129 | 170 | 237 | 312 | 383 | 445 | 519 | 171 | 194 | - | 39.00 | - | 13.00 | 19.00 | 24.00 | 72.00 |
| Retained Earnings | 7.1% | -1,500 | -1,613 | -1,566 | -1,527 | -1,500 | -1,400 | -1,400 | -1,328 | -1,200 | -1,100 | -1,100 | -980 | -892 | -805 | -752 | -701 | -661 | 600 | -563 | -528 | -474 |
| Additional Paid-In Capital | 0.6% | 1,665 | 1,654 | 1,594 | 1,586 | 1,575 | 1,567 | 1,568 | 1,566 | 1,547 | 1,533 | 1,517 | 1,500 | 1,063 | 1,000 | 751 | 740 | 636 | 613 | 583 | 553 | 546 |
| Shares Outstanding | 0.3% | 151 | 151 | 149 | 146 | 145 | 135 | 134 | 143 | 132 | 132 | 132 | 141 | 119 | 109 | 105 | 88.00 | 90.00 | 84.00 | 81.00 | 75.00 | 74.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 299.3% | 83,704 | -42,005 | -59,902 | -23,870 | -34,495 | -49,116 | -68,689 | -86,909 | -67,201 | -60,169 | -81,355 | -52,026 | -56,532 | -43,834 | -62,115 | -30,393 | -33,202 | -35,860 | -33,351 | -33,690 | -33,009 |
| Share Based Compensation | -26.8% | 9,184 | 12,541 | 6,823 | 11,068 | 7,000 | -1,000 | 2,100 | 14,356 | 14,000 | 16,300 | 16,618 | 33,521 | 28,300 | 7,400 | 11,068 | 5,621 | 2,075 | 1,757 | 1,882 | 1,458 | -173 |
| Cashflow From Investing | -199.1% | -30,229 | 30,501 | -6,168 | 16,269 | -2,990 | 10,379 | -43,671 | 3,288 | -631 | -2,475 | -514 | -52,076 | 14,911 | 11,205 | 1,450 | 4.00 | -44.00 | 457 | -1,135 | 238 | -6,435 |
| Cashflow From Financing | -99.1% | 421 | 47,047 | 25,238 | 49.00 | 275 | 135 | -850 | 55,997 | -7,361 | -7,162 | -55.00 | 403,389 | 35,265 | 241,092 | 81.00 | 98,354 | 20,695 | 28,284 | 56,880 | 4,694 | 4,492 |
TGTX Income Statement
2023-09-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenue: | ||||
| Revenue | $ 165,815 | $ 94 | $ 189,691 | $ 2,705 |
| Costs and expenses: | ||||
| Cost of revenue | 3,509 | 2 | 6,277 | 262 |
| Research and development: | ||||
| Noncash compensation | 2,915 | 3,249 | 10,162 | 7,471 |
| Other research and development | 11,838 | 17,552 | 48,581 | 88,246 |
| Total research and development | 14,753 | 20,801 | 58,743 | 95,717 |
| Selling, general and administrative: | ||||
| Noncash compensation | 6,269 | 3,740 | 18,386 | 663 |
| Other selling, general and administrative | 26,500 | 10,514 | 73,167 | 46,840 |
| Total selling, general and administrative | 32,769 | 14,254 | 91,553 | 47,503 |
| Total costs and expenses | 51,031 | 35,057 | 156,573 | 143,482 |
| Operating income (loss) | 114,784 | (34,963) | 33,118 | (140,777) |
| Other expense (income): | ||||
| Interest expense | 3,713 | 1,648 | 10,184 | 7,329 |
| Other income | (2,859) | (793) | (4,154) | (2,765) |
| Total other expense (income), net | 854 | 855 | 6,030 | 4,564 |
| Net income (loss) | $ 113,930 | $ (35,818) | $ 27,088 | $ (145,341) |
| Net income (loss) per common share: | ||||
| Basic (in dollars per share) | $ 0.8 | $ (0.26) | $ 0.19 | $ (1.08) |
| Diluted (in dollars per share) | $ 0.73 | $ (0.26) | $ 0.19 | $ (1.08) |
| Weighted-average shares outstanding: | ||||
| Basic (in shares) | 142,871,227 | 135,327,035 | 141,571,785 | 134,839,207 |
| Diluted (in shares) | 155,871,749 | 135,327,035 | 145,952,913 | 134,839,207 |
| Product [Member] | ||||
| Revenue: | ||||
| Revenue | $ 25,068 | $ 56 | $ 48,868 | $ 2,591 |
| License [Member] | ||||
| Revenue: | ||||
| Revenue | $ 140,747 | $ 38 | $ 140,823 | $ 114 |
TGTX Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 150,902 | $ 102,304 |
| Short-term investment securities | 78,257 | 59,374 |
| Accounts receivable, net | 39,320 | 0 |
| Inventories | 33,553 | 0 |
| Prepaid research and development | 5,001 | 4,237 |
| Other current assets | 12,081 | 2,359 |
| Total current assets | 319,114 | 168,274 |
| Restricted cash | 1,282 | 1,273 |
| Long-term investment securities | 0 | 12,404 |
| Right of use assets | 8,271 | 8,888 |
| Leasehold interest, net | 1,468 | 1,627 |
| Equipment, net | 133 | 307 |
| Goodwill | 799 | 799 |
| Total assets | 331,067 | 193,572 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 39,741 | 42,019 |
| Other current liabilities | 1,217 | 1,017 |
| Lease liability – current portion | 1,479 | 1,581 |
| Deferred revenue - current portion | 6,903 | 152 |
| Accrued compensation | 8,338 | 8,432 |
| Total current liabilities | 57,678 | 53,201 |
| Deferred revenue, non-current portion | 190 | 305 |
| Loan payable – non-current | 98,908 | 71,135 |
| Lease liability – non-current | 9,522 | 10,344 |
| Total liabilities | 166,298 | 134,985 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value per share (175,000,000 shares authorized, 151,490,731 and 146,426,697 shares issued, 151,449,422 and 146,385,388 shares outstanding at September 30, 2023 and December 31, 2022, respectively) | 151 | 146 |
| Additional paid-in capital | 1,664,797 | 1,585,708 |
| Treasury stock, at cost, 41,309 shares at September 30, 2023 and December 31, 2022 | (234) | (234) |
| Accumulated deficit | (1,499,945) | (1,527,033) |
| Total stockholders’ equity | 164,769 | 58,587 |
| Total liabilities and stockholders’ equity | $ 331,067 | $ 193,572 |
| Â CEO | Mr. Michael S. Weiss Esq. |
|---|---|
| Â WEBSITE | www.tgtherapeutics.com |
| Â EMPLOYEES | 244 |